<p>迷幻市場價值預計在未來幾年將增長約三倍。雖然絕對規模不大，但這種增長潛力將創造許多贏家股票。</p>
<p>迷幻藥物繼續主要用於治療用途。它們對疼痛障礙具有深刻的療效，特別在治療抑鬱症和其他心理健康障礙方面非常有用。</p>
<p>作為一組，迷幻藥物包括傳統上與幻覺和其他副作用相關聯的 LSD 等藥物，這使它們被認為具有危險性。然而，它們在治療難治性抑鬱症、恐慌障礙和阿片類藥物成癮方面的潛在療效使它們具有商業價值。</p>
<p>長期以來，娛樂用户一直支持迷幻藥物受到過度批評，並在治療心理健康障礙方面具有實際效用的觀念。製藥行業開始接受這種觀念，開闢了新的治療途徑和機會。在這個過程中，對於願意早期介入的人來説，投資迷幻股票的機會正在出現。</p>
<h2>Mind Medicine（MNMD）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Daniel Patrick Martin / Shutterstock.com</p>
<p><strong>Mind Medicine</strong>（納斯達克：<strong>MNMD</strong>）的主力候選藥物是 MM120，這是一種優化的 LSD 形式，用於治療廣泛性焦慮障礙。 LSD 和其他迷幻藥物（如 MDMA）在治療與壓力有關的障礙方面的潛在用途之一是該股受到如此多關注的原因。</p>
<p>然而，迷幻藥物和迷幻股票的世界仍然是非常不確定的領域。很大一部分機會取決於監管批准。FDA 最近就 MDMA 用於創傷後應激障礙的非約束性裁決引起了一些擔憂。儘管 Mind Medicine 使用的是 LSD 而不是 MDMA，但這一消息仍使 Mind Medicine 的股價下跌。</p>
<p>FDA 繼續認可 MDM、LSD 和其他迷幻藥物的治療潛力。預計 Mind Medicine 仍將在今年下半年啓動 MM120 的 3 期臨牀試驗。與此同時，該公司還計劃同時啓動其他研究，研究 MDMA 衍生物用於自閉症的治療。</p>
<h2>GH Research（GHRS）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Sisacorn / Shutterstock.com</p>
<p><strong>GH Research</strong>（納斯達克：<strong>GHRS</strong>）股票代表一家致力於開發各種治療精神疾病和神經疾病的療法的公司。該公司特別專注於開發 DMT，用於治療治療難治性抑鬱症（TRD）的患者。</p>
<p>GH Research 正在研究的 DMT 特定變體可以在幾種植物物種以及某些蟾蜍物種中自然發現。</p>
<p>無論如何，GH Research 股票在 2024 年表現非常出色，年初至今翻了一番多。這一成功使股價在撰寫時達到 12 美元。仍然有很大潛力，共識目標價高於 36 美元。</p>
<p>該公司用於治療 mebufotenin（5-MeO-DMT）吸入劑的 2b 期試驗非常成功，預計將於今年下半年結束。</p>
<p>同一藥物正在進行用於產後抑鬱症治療的 2a 期試驗。該公司的現金儲備可支持到 2026 年。這些最近的持續成功，加上資金支持，使 GH Research 成為值得關注的頂級迷幻股票之一。</p>
<h2>Atai Life Sciences（ATAI）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Billion Photos / Shutterstock</p>
<p><strong>Atai Life Sciences</strong>（納斯達克：<strong>ATAI</strong>）是另一家受到最近 FDA 關於 MDMA 用於創傷後應激障礙決定打擊的公司。股價在這一消息公佈後下跌了超過 10%，並持續走低。</p>
<p>該 FDA 決定是在 6 月 4 日作出的。該公司繼續收集關於治療難治性抑鬱症的短期迷幻療法的數據。Atai Life Sciences 最近還宣佈進一步進行溴酚菌素研究，用於治療重性抑鬱症（MDD）。</p>
<p>該試驗利用溴酚菌素的活性代謝物 psilocin，以實現兩小時的較短治療時間。該公司已經為此目的專利了 psilocin，命名為 ELE-101。</p>
<p>重要的是要記住，最近 FDA 的決定涉及 MDMA 而不是溴酚菌素。此外，它特別針對 MDMA 在治療創傷後應激障礙方面的使用。溴酚菌素及其代謝物不受該決定影響，並且 Atai Life Sciences 正在研究其在 PTSD 之外的其他用途。</p>
<p>_在本文發佈日期，Alex Sirois 對提及的證券沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者個人，遵守 InvestorPlace.com 的發佈指南。</p>
<p><em>在本文發佈日期，負責編輯對提及的證券沒有（直接或間接）任何持倉。</em></p>
<p>Alex Sirois 是 InvestorPlace 的自由撰稿人，他的個人股票投資風格側重於長期持有、積累財富的股票選擇。他曾在從電子商務到翻譯再到教育等多個行業工作，並利用他在喬治華盛頓大學獲得的工商管理碩士學位，通過這些技能過濾他的寫作。</p>

GHRS

<p>預計迷幻市場價值將翻三倍，為投資迷幻股票創造機會。Mind Medicine、GH Research 和 Atai Life Sciences 等公司正在開發利用 LSD 和 DMT 等迷幻物質治療心理健康障礙的療法。這些股票在臨牀試驗中表現出有希望的結果，並具有顯著增長潛力</p>

<p>The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.</p>
<div class="lb-trans"><p>迷幻市場價值預計在未來幾年將增長約三倍。雖然絕對規模不大，但這種增長潛力將創造許多贏家股票。</p>
</div><p>Psychedelics continue to be developed primarily for their therapeutic uses. They have deep efficacy for pain disorders and are especially useful in treating depression and other mental health disorders.</p>
<div class="lb-trans"><p>迷幻藥物繼續主要用於治療用途。它們對疼痛障礙具有深刻的療效，特別在治療抑鬱症和其他心理健康障礙方面非常有用。</p>
</div><p>As a group, psychedelics include drugs such as LSD that have traditionally been associated with hallucinations and other side effects that have given them a dangerous perception. However, their potential efficacy in treating resistant depression, panic disorders and opiate addiction makes them commercially valuable.</p>
<div class="lb-trans"><p>作為一組，迷幻藥物包括傳統上與幻覺和其他副作用相關聯的 LSD 等藥物，這使它們被認為具有危險性。然而，它們在治療難治性抑鬱症、恐慌障礙和阿片類藥物成癮方面的潛在療效使它們具有商業價值。</p>
</div><p>Recreational users have long supported the idea that psychedelics are much maligned and have real utility in treating mental health disorders. The pharmaceutical industry is beginning to get on board with that notion, opening new treatment pathways and opportunities overall. In the process, opportunities to invest in psychedelic stocks are emerging for those willing to get in early.</p>
<div class="lb-trans"><p>長期以來，娛樂用户一直支持迷幻藥物受到過度批評，並在治療心理健康障礙方面具有實際效用的觀念。製藥行業開始接受這種觀念，開闢了新的治療途徑和機會。在這個過程中，對於願意早期介入的人來説，投資迷幻股票的機會正在出現。</p>
</div><h2>Mind Medicine (MNMD)</h2>
<div class="lb-trans"><h2>Mind Medicine（MNMD）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Daniel Patrick Martin / Shutterstock.com</p>
<div class="lb-trans"><p>來源：Daniel Patrick Martin / Shutterstock.com</p>
</div><p><strong>Mind Medicine’s</strong> (NASDAQ:<strong>MNMD</strong>) lead candidate is MM120, an optimized form of LSD used to treat generalized anxiety disorder. The potential utility of LSD and other psychedelics, such as MDMA, in the treatment of stress-related disorders is one of the reasons the stock is receiving so much attention.</p>
<div class="lb-trans"><p><strong>Mind Medicine</strong>（納斯達克：<strong>MNMD</strong>）的主力候選藥物是 MM120，這是一種優化的 LSD 形式，用於治療廣泛性焦慮障礙。 LSD 和其他迷幻藥物（如 MDMA）在治療與壓力有關的障礙方面的潛在用途之一是該股受到如此多關注的原因。</p>
</div><p>However, the world of psychedelics and psychedelics stocks is still very much Wild West territory. A lot of the opportunity hinges upon regulatory approval. Recent non-binding judgments by the FDA related to the use of MDMA for post-traumatic stress disorder are causing some concern. While Mind Medicine utilizes LSD and not MDMA, the news still sent Mind Medicine’s shares lower.</p>
<div class="lb-trans"><p>然而，迷幻藥物和迷幻股票的世界仍然是非常不確定的領域。很大一部分機會取決於監管批准。FDA 最近就 MDMA 用於創傷後應激障礙的非約束性裁決引起了一些擔憂。儘管 Mind Medicine 使用的是 LSD 而不是 MDMA，但這一消息仍使 Mind Medicine 的股價下跌。</p>
</div><p>The FDA continues to recognize the therapeutic potential of MDM, LSD and other psychedelics. Mind Medicine is still expected to initiate a Phase 3 clinical trial for MM120 in the second half of this year. Meanwhile, the company is concurrently planning to initiate other studies of MDMA derivatives for the treatment of autism.</p>
<div class="lb-trans"><p>FDA 繼續認可 MDM、LSD 和其他迷幻藥物的治療潛力。預計 Mind Medicine 仍將在今年下半年啓動 MM120 的 3 期臨牀試驗。與此同時，該公司還計劃同時啓動其他研究，研究 MDMA 衍生物用於自閉症的治療。</p>
</div><h2>GH Research (GHRS)</h2>
<div class="lb-trans"><h2>GH Research（GHRS）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Sisacorn / Shutterstock.com</p>
<div class="lb-trans"><p>來源：Sisacorn / Shutterstock.com</p>
</div><p><strong>GH Research</strong> (NASDAQ:<strong>GHRS</strong>) stock represents a company engaged in the development of various therapies to treat psychiatric and neurological disorders. The company is especially focused on the development of DMT for use in treating patients with treatment-resistant depression (TRD).</p>
<div class="lb-trans"><p><strong>GH Research</strong>（納斯達克：<strong>GHRS</strong>）股票代表一家致力於開發各種治療精神疾病和神經疾病的療法的公司。該公司特別專注於開發 DMT，用於治療治療難治性抑鬱症（TRD）的患者。</p>
</div><p>The particular variant of DMT that GH research is studying can be found naturally in several species of plants as well as certain toad species.</p>
<div class="lb-trans"><p>GH Research 正在研究的 DMT 特定變體可以在幾種植物物種以及某些蟾蜍物種中自然發現。</p>
</div><p>Anyway, GH research stock has done extraordinarily well in 2024, more than doubling year-to-date. That success has brought share prices to $12 at the time of writing. Plenty of potential remains, with a consensus target price above $36.</p>
<div class="lb-trans"><p>無論如何，GH Research 股票在 2024 年表現非常出色，年初至今翻了一番多。這一成功使股價在撰寫時達到 12 美元。仍然有很大潛力，共識目標價高於 36 美元。</p>
</div><p>The company’s phase 2b trial for a mebufotenin (5-MeO-DMT) inhalant has been very successful and is expected to end in the second half of this year.</p>
<div class="lb-trans"><p>該公司用於治療 mebufotenin（5-MeO-DMT）吸入劑的 2b 期試驗非常成功，預計將於今年下半年結束。</p>
</div><p>That same drug is being tested in a phase 2a trial for the treatment of postpartum depression. The company has a cash runway into 2026. That funding, combined with those recent ongoing successes, makes GH Research one of the top psychedelic stocks to watch.</p>
<div class="lb-trans"><p>同一藥物正在進行用於產後抑鬱症治療的 2a 期試驗。該公司的現金儲備可支持到 2026 年。這些最近的持續成功，加上資金支持，使 GH Research 成為值得關注的頂級迷幻股票之一。</p>
</div><h2>Atai Life Sciences (ATAI)</h2>
<div class="lb-trans"><h2>Atai Life Sciences（ATAI）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Billion Photos / Shutterstock</p>
<div class="lb-trans"><p>來源：Billion Photos / Shutterstock</p>
</div><p><strong>Atai Life Sciences</strong> (NASDAQ:<strong>ATAI</strong>) is another stock that was hit hard by the recent FDA decision on MDMA for PTSD. Shares fell more than 10% in the wake of the news and have continued downward since.</p>
<div class="lb-trans"><p><strong>Atai Life Sciences</strong>（納斯達克：<strong>ATAI</strong>）是另一家受到最近 FDA 關於 MDMA 用於創傷後應激障礙決定打擊的公司。股價在這一消息公佈後下跌了超過 10%，並持續走低。</p>
</div><p>That FDA decision fell on June 4. The company continues to collect data on short-term psychedelic therapies for treatment-resistant depression. Atai Life Sciences also recently announced further ongoing studies of psilocybin for the treatment of major depressive disorder (MDD).</p>
<div class="lb-trans"><p>該 FDA 決定是在 6 月 4 日作出的。該公司繼續收集關於治療難治性抑鬱症的短期迷幻療法的數據。Atai Life Sciences 最近還宣佈進一步進行溴酚菌素研究，用於治療重性抑鬱症（MDD）。</p>
</div><p>That trial utilizes psilocin, the active metabolite of psilocybin in order to affect a shorter treatment duration of two hours. The company has patented psilocin for that purpose under the name ELE-101.</p>
<div class="lb-trans"><p>該試驗利用溴酚菌素的活性代謝物 psilocin，以實現兩小時的較短治療時間。該公司已經為此目的專利了 psilocin，命名為 ELE-101。</p>
</div><p>It’s important to remember that the recent FDA decision related to MDMA and not psilocybin. Furthermore, it was specifically for the use of MDMA in the treatment of PTSD. Psilocybin and its metabolites are unaffected by the decision and are being studied for other purposes outside of PTSD by Atai Life Sciences.</p>
<div class="lb-trans"><p>重要的是要記住，最近 FDA 的決定涉及 MDMA 而不是溴酚菌素。此外，它特別針對 MDMA 在治療創傷後應激障礙方面的使用。溴酚菌素及其代謝物不受該決定影響，並且 Atai Life Sciences 正在研究其在 PTSD 之外的其他用途。</p>
</div><p><em>On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines.</em></p>
<div class="lb-trans"><p>_在本文發佈日期，Alex Sirois 對提及的證券沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者個人，遵守 InvestorPlace.com 的發佈指南。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在本文發佈日期，負責編輯對提及的證券沒有（直接或間接）任何持倉。</em></p>
</div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p>
<div class="lb-trans"><p>Alex Sirois 是 InvestorPlace 的自由撰稿人，他的個人股票投資風格側重於長期持有、積累財富的股票選擇。他曾在從電子商務到翻譯再到教育等多個行業工作，並利用他在喬治華盛頓大學獲得的工商管理碩士學位，通過這些技能過濾他的寫作。</p>
</div>

3 只迷幻藥股票飛向月球及更遠